| Code | CSB-RA011048MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to dazukibart, targeting interferon beta-1 (IFNB1), a critical type I interferon involved in antiviral immunity and immune regulation. IFNB1 functions as a pleiotropic cytokine that modulates both innate and adaptive immune responses by inducing expression of interferon-stimulated genes, enhancing antigen presentation, and regulating inflammatory pathways. This protein plays essential roles in host defense against viral infections and has significant implications in autoimmune diseases, particularly multiple sclerosis, where dysregulated interferon signaling contributes to disease pathogenesis and therapeutic responses.
Dazukibart represents a therapeutic antibody designed to neutralize IFNB1 activity, providing researchers with a valuable tool for investigating interferon-mediated biological processes. This biosimilar enables studies examining the role of IFNB1 in neuroimmunology, viral pathogenesis, and autoimmune disease mechanisms. It serves as an important reagent for exploring interferon signaling cascades, evaluating therapeutic interventions targeting type I interferons, and understanding the complex balance between antiviral immunity and autoimmune regulation in various experimental models.
There are currently no reviews for this product.